Sumanirole

Sumanirole

Sumanirole is a psychoactive drug and research chemical that acts as a dopamine agonist. It was developed by Pfizer and is most commonly used in scientific research. Sumanirole has been studied for potential use in the treatment of Parkinson's disease and Restless Legs Syndrome (RLS).

Pharmacology

Sumanirole is a highly selective D2 receptor agonist, which means it mimics the action of dopamine at this receptor. This is in contrast to many other dopamine agonists which also have activity at other dopamine receptor subtypes. The D2 receptor is primarily found in the striatum and nigrostriatal pathway, areas of the brain that are involved in movement and reward.

Clinical Trials

In clinical trials, Sumanirole has shown promise for the treatment of Parkinson's disease and Restless Legs Syndrome. However, it has not been approved for these uses by any regulatory authority. The drug has been well tolerated in clinical trials, with the most common side effects being nausea, dizziness, and somnolence.

Chemistry

Sumanirole is a synthetic compound that belongs to the class of phenylpiperazines. It is structurally similar to other dopamine agonists such as ropinirole and pramipexole.

History

Sumanirole was first synthesized by Pfizer in the late 1990s as part of their research into treatments for Parkinson's disease. Despite showing promise in early clinical trials, development of the drug was discontinued for unknown reasons.

See Also

• Dopamine agonist
• Parkinson's disease
• Restless Legs Syndrome
• Pfizer